December 18, 2017 / 12:12 PM / 6 months ago

BRIEF-RXi Pharma Announces Meets Secondary Objective With RXI-109 For Dermal Scarring

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH RXI-109 FOR DERMAL SCARRING

* RXI PHARMACEUTICALS CORP - RXI-109 MEETS SECONDARY OBJECTIVE AS IT WAS SHOWN TO BE SAFE AND WELL TOLERATED

* RXI PHARMACEUTICALS CORP -RXI-109 STUDY SUCCESSFULLY MEETS PRIMARY EFFECTIVENESS OBJECTIVE WITH STATISTICALLY SIGNIFICANT OUTCOMES

* RXI PHARMACEUTICALS - FULL STUDY RESULTS SHOW RXI-109 WAS SAFE, WELL TOLERATED FOR ALL DOSAGE GROUPS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below